{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:12:09Z","timestamp":1789805529158,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Aalborg University Hospital","id":[{"id":"https:\/\/ror.org\/02jk5qe80","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Prostate-specific membrane antigen (PSMA) PET has emerged as a sensitive imaging modality for prostate cancer (PC), but its role in intraprostatic tumour localisation relative to multiparametric MRI (mpMRI) and differences between [\u00b9\u2078F]- and [\u2076\u2078Ga]-PSMA ligands remain unclear. This study compared the diagnostic performance of [\u00b9\u2078F]F-PSMA-1007 PET\/CT, [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT, and mpMRI for intraprostatic tumour localisation and detection of clinically significant prostate cancer (csPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective single-centre study, patients with biopsy-proven high-risk PC undergoing radical prostatectomy were recruited. All patients underwent [\u00b9\u2078F]F-PSMA-1007 PET\/CT and [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT. Following a protocol amendment, mpMRI was added as a secondary exploratory imaging modality and performed in a subset of patients prior to surgery. Histopathology was the reference standard; csPC was defined as \u2265ISUP3 or ISUP2 with tertiary Gleason 5 pattern. Diagnostic performance was assessed on a per-patient and per-region basis, dividing the prostate into sextants and using mixed regression models to account for clustering. Secondary analyses evaluated the detection of pathological features beyond the prostate, including extraprostatic extension (EPE) and seminal vesicle invasion (SVI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty patients were included in the analysis of PSMA PET\/CT, and 45 patients had mpMRI. At the patient level, [\u00b9\u2078F]F-PSMA-1007 PET\/CT, [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT and mpMRI demonstrated sensitivities of 98%, 100%, and 96%, respectively, for the detection of csPC, with corresponding diagnostic accuracies of 96%, 98%, and 93%, respectively. Of 300 sextants, 205 contained csPC. [\u00b9\u2078F]F-PSMA-1007 PET\/CT identified csPC in 143\/300 sextants (accuracy: 69.8%, 95%CI 64.0\u201375.6). [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT detected csPC in 136\/300 sextants (accuracy: 67.8%, 95%CI 62.3\u201373.4). mpMRI identified csPC in 89\/270 sextants (accuracy: 62.9%, 95%CI 56.3\u201369.4). PSMA PET ligands showed significantly higher sensitivity than mpMRI (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), whereas mpMRI demonstrated higher specificity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). No significant differences were observed between [\u00b9\u2078F]F-PSMA-1007 and [\u2076\u2078Ga]Ga-PSMA-11. Detection of pathological features of local tumour extension was limited across all modalities. Sensitivity for EPE was 12%, 23%, and 9%, and sensitivity for SVI was 30%, 30%, and 14% for [\u00b9\u2078F]F-PSMA-1007 PET\/CT, [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT, and mpMRI, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PSMA PET\/CT ligands provide higher sensitivity than mpMRI for intraprostatic tumour localisation, while no statistically significant differences in diagnostic performance were detected between [\u00b9\u2078F]- and [\u2076\u2078Ga]-PSMA ligands in this cohort. These findings support the potential complementary role of PSMA PET and mpMRI for preoperative intraprostatic tumour localisation in high-risk PC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08191-9","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:34:07Z","timestamp":1789803247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Head-to-head comparison of [\u00b9\u2078F]F-PSMA-1007 PET\/CT and [\u2076\u2078Ga]Ga-PSMA-11 PET\/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4029-3197","authenticated-orcid":false,"given":"Farid","family":"Gossili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Harving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid Christine","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Bouchelouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Henrik","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Johannes","family":"Leusink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja Morratz","family":"Laursen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle D.","family":"Zacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"8191_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"8191_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"key":"8191_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/JU.0000000000001389","volume":"205","author":"A Pooli","year":"2021","unstructured":"Pooli A, Johnson DC, Shirk J, Markovic D, Sadun TY, Sisk AE Jr., et al. Predicting Pathological Tumor Size in Prostate Cancer Based on Multiparametric Prostate Magnetic Resonance Imaging and Preoperative Findings. J Urol. 2021;205:444\u201351. https:\/\/doi.org\/10.1097\/JU.0000000000001389.","journal-title":"J Urol"},{"key":"8191_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","volume":"70","author":"M de Rooij","year":"2016","unstructured":"de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. Eur Urol. 2016;70:233\u201345. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.029.","journal-title":"Eur Urol"},{"key":"8191_CR5","doi-asserted-by":"publisher","first-page":"110757","DOI":"10.1016\/j.ejrad.2023.110757","volume":"161","author":"Y Lin","year":"2023","unstructured":"Lin Y, Yilmaz EC, Belue MJ, Turkbey B. Prostate MRI and image Quality: It is time to take stock. Eur J Radiol. 2023;161:110757. https:\/\/doi.org\/10.1016\/j.ejrad.2023.110757.","journal-title":"Eur J Radiol"},{"key":"8191_CR6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023). J Urol. 2023;209:1082\u201390. https:\/\/doi.org\/10.1097\/JU.0000000000003452.","journal-title":"J Urol"},{"key":"8191_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, et al. NCCN Guidelines(R) Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22:140\u201350. https:\/\/doi.org\/10.6004\/jnccn.2024.0019.","journal-title":"J Natl Compr Canc Netw"},{"key":"8191_CR8","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626\u201338. https:\/\/doi.org\/10.1007\/s00259-021-05245-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8191_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023;83:405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol"},{"key":"8191_CR10","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1007\/s00330-023-10436-2","volume":"34","author":"J Ma","year":"2024","unstructured":"Ma J, Yang Q, Ye X, Xu W, Chang Y, Chen R, et al. Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis. Eur Radiol. 2024;34:4017\u201337. https:\/\/doi.org\/10.1007\/s00330-023-10436-2.","journal-title":"Eur Radiol"},{"key":"8191_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00259-023-06392-0","volume":"51","author":"F Gossili","year":"2023","unstructured":"Gossili F, Mogensen AW, Konnerup TC, Bouchelouche K, Alberts I, Afshar-Oromieh A, et al. The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2023;51:281\u201394. https:\/\/doi.org\/10.1007\/s00259-023-06392-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8191_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.crad.2020.06.031","volume":"75","author":"RW Foley","year":"2020","unstructured":"Foley RW, Redman SL, Graham RN, Loughborough WW, Little D. Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls. Clin Radiol. 2020;75:903\u201313. https:\/\/doi.org\/10.1016\/j.crad.2020.06.031.","journal-title":"Clin Radiol"},{"key":"8191_CR13","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1007\/s00259-025-07208-z","volume":"52","author":"A Kivikallio","year":"2025","unstructured":"Kivikallio A, Malaspina S, Saarinen I, Seppanen M, Anttinen M, Jambor I, et al. Prospective comparison of (18)F-PSMA-1007 PET\/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:3709\u201319. https:\/\/doi.org\/10.1007\/s00259-025-07208-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8191_CR14","doi-asserted-by":"publisher","unstructured":"Talavera Cobo V, Yanez Ruiz CA, Tapia Tapia MD, Calva Lopez A, Munoz Bastidas CA, Ancizu Marckert FJ, et al. Diagnostic Accuracy of PSMA-PET\/CT vs. mpMRI in Primary Staging of Intermediate- and High-Risk Prostate Cancer. Med Sci (Basel). 2026;14. https:\/\/doi.org\/10.3390\/medsci14010064.","DOI":"10.3390\/medsci14010064"},{"key":"8191_CR15","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.121.262398","volume":"63","author":"I Sonni","year":"2022","unstructured":"Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, et al. Head-to-Head Comparison of (68)Ga-PSMA-11 PET\/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2022;63:847\u201354. https:\/\/doi.org\/10.2967\/jnumed.121.262398.","journal-title":"Soc Nuclear Med"},{"key":"8191_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41824-024-00234-4","volume":"9","author":"E Hvittfeldt","year":"2025","unstructured":"Hvittfeldt E, Hedeer F, Thimansson E, Sandeman K, Minarik D, Ingvar J, et al. Semi-standardized evaluation of extraprostatic extension and seminal vesicle invasion with [(18)F]PSMA-1007 PET\/CT: a comparison to MRI using histopathology as reference. EJNMMI Rep. 2025;9:1. https:\/\/doi.org\/10.1186\/s41824-024-00234-4.","journal-title":"EJNMMI Rep"},{"key":"8191_CR17","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1148\/radiol.2019190687","volume":"293","author":"UJ Muehlematter","year":"2019","unstructured":"Muehlematter UJ, Burger IA, Becker AS, Schawkat K, H\u00f6tker AM, Reiner CS, et al. Diagnostic Accuracy of Multiparametric MRI versus (68)Ga-PSMA-11 PET\/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer. Radiology. 2019;293:350\u20138. https:\/\/doi.org\/10.1148\/radiol.2019190687.","journal-title":"Radiology"},{"key":"8191_CR18","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1007\/s00259-025-07134-0","volume":"52","author":"H Lin","year":"2025","unstructured":"Lin H, Yao F, Yi X, Yuan Y, Xu J, Chen L, et al. Prediction of adverse pathology in prostate cancer using a multimodal deep learning approach based on [(18)F]PSMA-1007 PET\/CT and multiparametric MRI. Eur J Nucl Med Mol Imaging. 2025;52:2814\u201325. https:\/\/doi.org\/10.1007\/s00259-025-07134-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8191_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/JNUMED.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-Head Comparison of Ga-68-PSMA-11 with F-18-PSMA-1007 PET\/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J Nucl Med. 2020;61:527\u201332. https:\/\/doi.org\/10.2967\/JNUMED.119.234187.","journal-title":"J Nucl Med"},{"key":"8191_CR20","doi-asserted-by":"publisher","first-page":"e012799","DOI":"10.1136\/bmjopen-2016-012799","volume":"6","author":"JF Cohen","year":"2016","unstructured":"Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6:e012799. https:\/\/doi.org\/10.1136\/bmjopen-2016-012799.","journal-title":"BMJ Open"},{"key":"8191_CR21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/RLU.0000000000001681","volume":"42","author":"JB Nielsen","year":"2017","unstructured":"Nielsen JB, Zacho HD, Haberkorn U, Nielsen KM, Dettmann K, Langkilde NC, et al. A Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET\/CT in Prostate Cancer: The Results of 2 Prospective, Multicenter Trials. Clin Nucl Med. 2017;42:520\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000001681.","journal-title":"Clin Nucl Med"},{"key":"8191_CR22","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"G van Leenders","year":"2020","unstructured":"van Leenders G, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020;44:e87\u201399. https:\/\/doi.org\/10.1097\/PAS.0000000000001497.","journal-title":"Am J Surg Pathol"},{"key":"8191_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019;76:340\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","journal-title":"Eur Urol"},{"key":"8191_CR24","doi-asserted-by":"publisher","first-page":"111274","DOI":"10.1016\/j.ejrad.2023.111274","volume":"170","author":"X Ren","year":"2024","unstructured":"Ren X, Nur Salihin Yusoff M, Hartini Mohd Taib N, Zhang L, Wang K. (68)Ga-prostate specific membrane antigen-11 PET\/CT versus multiparametric MRI in the detection of primary prostate cancer: A systematic review and head-to-head comparative meta-analysis. Eur J Radiol. 2024;170:111274. https:\/\/doi.org\/10.1016\/j.ejrad.2023.111274.","journal-title":"Eur J Radiol"},{"key":"8191_CR25","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1097\/RLU.0000000000004646","volume":"48","author":"YF Wang","year":"2023","unstructured":"Wang YF, Lo CY, Chen LY, Chang CW, Huang YT, Huang YY, et al. Comparing the Detection Performance Between Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen PET\/CT in Patients With Localized Prostate Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med. 2023;48:e321\u201331. https:\/\/doi.org\/10.1097\/RLU.0000000000004646.","journal-title":"Clin Nucl Med"},{"key":"8191_CR26","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.euo.2023.04.006","volume":"6","author":"L Exterkate","year":"2023","unstructured":"Exterkate L, Hermsen R, Kusters-Vandevelde HVN, Prette JF, Baas DJH, Somford DM, et al. Head-to-Head Comparison of (18)F-PSMA-1007 Positron Emission Tomography\/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Whole-mount Histopathology as Reference in Localisation and Staging of Primary Prostate Cancer. Eur Urol Oncol. 2023;6:574\u201381. https:\/\/doi.org\/10.1016\/j.euo.2023.04.006.","journal-title":"Eur Urol Oncol"},{"key":"8191_CR27","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1001\/jamaoncol.2024.3196","volume":"10","author":"N Mookerji","year":"2024","unstructured":"Mookerji N, Pfanner T, Hui A, Huang G, Albers P, Mittal R, et al. Fluorine-18 Prostate-Specific Membrane Antigen-1007 PET\/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer. JAMA Oncol. 2024;10:1097\u2013103. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3196.","journal-title":"JAMA Oncol"},{"key":"8191_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00345-023-04729-w","volume":"42","author":"Z Mai","year":"2024","unstructured":"Mai Z, Zhu M, Feng T, Zhou Z, Zhou Y, Wang D, et al. Comparisons of mpMRI, (68)Ga-PSMA PET\/CT and mpMRI combined with (68)Ga-PSMA PET\/CT in diagnosing prostate cancer based on tumor detection, localization and staging. World J Urol. 2024;42:29. https:\/\/doi.org\/10.1007\/s00345-023-04729-w.","journal-title":"World J Urol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08191-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08191-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08191-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:34:09Z","timestamp":1789803249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08191-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":28,"alternative-id":["8191"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08191-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Danish Medical Counsel, the North Denmark Region Committee on Health Research Ethics (approval number: N-20200025).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate and publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Was obtained from all individual participants in\u00adcluded in the study.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}